Zacks Investment Research lowered shares of ReNeuron (OTCMKTS:RNUGF) from a buy rating to a hold rating in a research report sent to investors on Friday.
According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom. “
Shares of ReNeuron stock opened at $1.35 on Friday. The firm has a market cap of $42.72 and a price-to-earnings ratio of -1.35. ReNeuron has a 1-year low of $0.02 and a 1-year high of $1.35.
COPYRIGHT VIOLATION NOTICE: “ReNeuron (RNUGF) Downgraded by Zacks Investment Research to “Hold”” was reported by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3342220/reneuron-rnugf-downgraded-by-zacks-investment-research-to-hold.html.
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase III clinical trial for the treatment of patients left disabled by the effects of a stroke, as well as that has been completed Phase I clinical trial to treat critical limb ischaemia, a side effect of diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ReNeuron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron and related companies with MarketBeat.com's FREE daily email newsletter.